ISSN: 2218-6751
Journal Home
Journal Guideline
Translational Lung Cancer Research Q2 Unclaimed
Translational Lung Cancer Research is a journal indexed in SJR in Oncology with an H index of 55. It has an SJR impact factor of 1,056 and it has a best quartile of Q2. It has an SJR impact factor of 1,056.
Type: Journal
Type of Copyright:
Languages:
Open Access Policy:
Type of publications:
Publication frecuency: -
- €
Inmediate OANPD
Embargoed OA- €
Non OAMetrics
1,056
SJR Impact factor55
H Index227
Total Docs (Last Year)867
Total Docs (3 years)8337
Total Refs3085
Total Cites (3 years)739
Citable Docs (3 years)3.42
Cites/Doc (2 years)36.73
Ref/DocOther journals with similar parameters
Frontiers in Oncology Q2
International Journal of Oncology Q2
Cancer Epidemiology Q2
Familial Cancer Q2
Journal of Geriatric Oncology Q2
Compare this journals
Aims and Scope
Best articles by citations
Improving outcomes for brain metastases in EGFR mutated NSCLC
View moreCombination immune checkpoint inhibitors with platinum-based chemotherapy in advanced non-small cell lung cancer: what's known and what's next
View moreSpread through air spaces in lung neuroendocrine tumor
View moreSurveillance imaging for non-small cell lung cancer: mounting evidence that less is more
View moreNew first-line treatment strategies for advanced lung squamous cell carcinoma
View moreScreening of potential biomarkers and their predictive value in early stage non-small cell lung cancer: a bioinformatics analysis
View moreBroad-based genomic sequencing in advanced non-small cell lung cancer in the dock
View moreCT-based radiomics signature for the stratification of N2 disease risk in clinical stage I lung adenocarcinoma
View moreFlexible bronchoscopy-guided microwave ablation in peripheral porcine lung: a new minimally-invasive ablation
View moreErlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer
View moreLorlatinib: an additional option for ALK-positive non-small cell lung cancer?
View moreTargeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?
View moreSurveillance of ground glass nodules - when is enough, enough?
View moreImpact of surveillance frequency on survival in non-small cell lung cancer (NSCLC) survivors
View moreMinimal residual disease after radical surgery in EGFR-mutant non-small cell lung cancer
View moreImpact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer
View moreAwareness: potential toxicities of carbon nanotubes
View moreRobot-assisted thoracoscopic surgery versus thoracotomy for c-N2 stage NSCLC: short-term outcomes of a randomized trial
View moreDo EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)? - the shifting paradigm of therapeutics
View moreChallenges and countermeasures of thoracic oncology in the epidemic of COVID-19
View moreOptimal management of pulmonary ground-glass opacity nodules
View moreCyclin D1 expression as a potential prognostic factor in advanced KRAS-mutant non-small cell lung cancer
View moreApplication of the CARE guideline as reporting standard in the Translational Lung Cancer Research
View moreThird-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
View more
Comments